Paclitaxel Treatment Options in Canada

A collection of 342 research studies where Paclitaxel is the interventional treatment. These studies are located in the Canada . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Home

Canada

All Treatments

Paclitaxel

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251

Active Not Recruiting

This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/05/2025

Locations: Research Site, Springdale, Arkansas +145 locations

Research Site, Springdale, Arkansas

Research Site, Beverly Hills, California

Research Site, Glendale, California

Research Site, Los Alamitos, California

Research Site, Orange, California

Research Site, New Haven, Connecticut

Research Site, Fort Wayne, Indiana

Research Site, Lexington, Kentucky

Research Site, Louisville, Kentucky

Research Site, Shreveport, Louisiana

Research Site, Minneapolis, Minnesota

Research Site, Las Vegas, Nevada

Research Site, East Brunswick, New Jersey

Research Site, Summit, New Jersey

Research Site, Commack, New York

Research Site, Durham, North Carolina

Research Site, Greenville, South Carolina

Research Site, Germantown, Tennessee

Research Site, Nashville, Tennessee

Research Site, Fort Worth, Texas

Research Site, Ogden, Utah

Research Site, Tacoma, Washington

Research Site, Goiânia, Not set

Research Site, Ijuí, Not set

Research Site, Natal, Not set

Research Site, Porto Alegre, Not set

Research Site, São Paulo, Not set

Research Site, Panagyurishte, Not set

Research Site, Sofia, Not set

Research Site, Edmonton, Alberta

Research Site, Toronto, Ontario

Research Site, Montreal, Quebec

Research Site, Quebec City, Quebec

Research Site, Sherbrooke, Quebec

Research Site, Montreal, Not set

Research Site, Beijing, Not set

Research Site, Changsha, Not set

Research Site, Chongqing, Not set

Research Site, Guangzhou, Not set

Research Site, Kunming, Not set

Research Site, Nanning, Not set

Research Site, Qingdao, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Tianjin, Not set

Research Site, Wuhan, Not set

Research Site, Zhengzhou, Not set

Research Site, Augsburg, Not set

Research Site, Berlin, Not set

Research Site, Erlangen, Not set

Research Site, Hamburg, Not set

Research Site, Heidelberg, Not set

Research Site, Kiel, Not set

Research Site, Leipzig, Not set

Research Site, Muenster, Not set

Research Site, Mönchengladbach, Not set

Research Site, München, Not set

Research Site, Paderborn, Not set

Research Site, Tübingen, Not set

Research Site, Gurgaon, Not set

Research Site, Howrah, Not set

Research Site, Nagpur, Not set

Research Site, Nashik, Not set

Research Site, New Delhi, Not set

Research Site, Raipur, Not set

Research Site, Rishikesh, Not set

Research Site, Surat, Not set

Research Site, Thiruvananthapuram, Not set

Research Site, Bologna, Not set

Research Site, Candiolo, Not set

Research Site, Livorno, Not set

Research Site, Milano, Not set

Research Site, Naples, Not set

Research Site, Napoli, Not set

Research Site, Negrar, Not set

Research Site, Padova, Not set

Research Site, Roma, Not set

Research Site, Rozzano, Not set

Research Site, Chuo-ku, Not set

Research Site, Hidaka-shi, Not set

Research Site, Hiroshima-shi, Not set

Research Site, Kawasaki-shi, Not set

Research Site, Koto-ku, Not set

Research Site, Nagoya-shi, Not set

Research Site, Ota-shi, Not set

Research Site, Shinjuku-ku, Not set

Research Site, Goyang-si, Not set

Research Site, Seoul, Not set

Research Site, Lima, Not set

Research Site, Bacolod, Not set

Research Site, Cebu City, Not set

Research Site, Davao City, Not set

Research Site, Iloilo, Not set

Research Site, Quezon City, Not set

Research Site, San Juan, Not set

Research Site, Biała Podlaska, Not set

Research Site, Białystok, Not set

Research Site, Bydgoszcz, Not set

Research Site, Koszalin, Not set

Research Site, Lublin, Not set

Research Site, Rzeszów, Not set

Research Site, Warszawa, Not set

Research Site, Moscow, Not set

Research Site, Saint Petersburg, Not set

Research Site, Ar Riyāḑ, Not set

Research Site, Dammam, Not set

Research Site, Jeddah, Not set

Research Site, Riyadh, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Sevilla, Not set

Research Site, Vigo, Not set

Research Site, Kaohsiung, Not set

Research Site, Taichung, Not set

Research Site, Tainan, Not set

Research Site, Taipei City, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Bangkok, Not set

Research Site, Chiang Mai, Not set

Research Site, Hat Yai, Not set

Research Site, Khon Kaen, Not set

Conditions: Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer

Learn More ›

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

NCT03635567

Completed

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women with persistent, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens include: paclitaxel plus cisplatin with or without bevacizumab and paclitaxel plus carboplatin with or without bevacizumab. The prim... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/29/2025

Locations: Alaska Women's Cancer Care ( Site 1770), Anchorage, Alaska +148 locations

Alaska Women's Cancer Care ( Site 1770), Anchorage, Alaska

Arizona Oncology Associates, PC- HAL ( Site 8005), Phoenix, Arizona

UC Irvine Health ( Site 1796), Orange, California

Smilow Cancer Hospital at Yale New Haven ( Site 1809), New Haven, Connecticut

H. Lee Moffitt Cancer Center and Research Institute ( Site 1754), Tampa, Florida

Georgia Cancer Center at Augusta University ( Site 1767), Augusta, Georgia

Barbara Ann Karmanos Cancer Institute ( Site 1785), Detroit, Michigan

Henry Ford Health System ( Site 1810), Detroit, Michigan

Washington University School of Medicine ( Site 1779), Saint Louis, Missouri

Cancer Institute of New Jersey at University Hospital ( Site 1762), Newark, New Jersey

Holy Name Medical Center ( Site 1776), Teaneck, New Jersey

Mount Sinai Chelsea ( Site 1760), New York, New York

Columbia University Medical Center ( Site 1800), New York, New York

OSU Wexner Medical Center ( Site 1817), Hilliard, Ohio

University of Oklahoma- Stephenson Oklahoma Cancer Center ( Site 1784), Oklahoma City, Oklahoma

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1768), Tulsa, Oklahoma

MUSC Hollings Cancer Center ( Site 1819), Charleston, South Carolina

West Cancer Center - East Campus ( Site 1763), Germantown, Tennessee

Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio, Texas

Seattle Cancer Care Alliance ( Site 1777), Seattle, Washington

Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1006), Berazategui, Buenos Aires

Hospital Aleman ( Site 1005), Buenos Aires, Not set

Hospital de Oncologia Angel Roffo ( Site 1003), Buenos Aires, Not set

Instituto Medico Especializado Alexander Fleming ( Site 1009), Buenos Aires, Not set

Centro Oncologico Riojano Integral ( Site 1004), La Rioja, Not set

Centro Medico San Roque ( Site 1001), Tucuman, Not set

Royal North Shore Hospital ( Site 1514), St Leonards, New South Wales

Mater Misericordiae Ltd Mater Cancer Care Centre ( Site 1521), South Brisbane, Queensland

Flinders Medical Centre ( Site 1513), Bedford Park, South Australia

St John of God Subiaco Hospital ( Site 1512), Subiaco, Western Australia

Monash Health-Monash Medical Centre ( Site 1519), Clayton, Not set

Tom Baker Cancer Centre ( Site 1728), Calgary, Alberta

BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 1734), Kelowna, British Columbia

BC Cancer - Vancouver Center ( Site 1722), Vancouver, British Columbia

CancerCare Manitoba ( Site 1725), Winnipeg, Manitoba

Queen Elizabeth II Health Sciences Centre ( Site 1731), Halifax, Nova Scotia

Juravinski Cancer Centre ( Site 1735), Hamilton, Ontario

London Regional Cancer Program - London HSC ( Site 1723), London, Ontario

The Ottawa Hospital Cancer Centre ( Site 1736), Ottawa, Ontario

Sunnybrook Research Institute ( Site 1733), Toronto, Ontario

Princess Margaret Cancer Centre ( Site 1732), Toronto, Ontario

CIUSSS du Saguenay-Lac-St-Jean ( Site 1729), Chicoutimi, Quebec

CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 1726), Montreal, Quebec

Centre Hospitalier de l Universite de Montreal - CHUM ( Site 1721), Montreal, Quebec

CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 1730), Sherbrooke, Quebec

CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 1724), Quebec, Not set

Oncocentro ( Site 1065), Vina del Mar, Valparaiso

Fundacion Arturo Lopez Perez FALP ( Site 1061), Santiago, Not set

Sociedad Oncovida S.A. ( Site 1069), Santiago, Not set

Centro de Cancer Nuestra Senora de la Esperanza ( Site 1063), Santiago, Not set

Instituto Clinico Oncologico del Sur ( Site 1062), Temuco, Not set

Sociedad de Oncologia y Hematologia del Cesar Ltda. ( Site 1103), Valledupar, Cesar

Instituto Nacional de Cancerologia E.S.E ( Site 1095), Bogota, Cundinamarca

Hemato Oncologos S.A. ( Site 1100), Cali, Valle

Biomelab S A S ( Site 1104), Barranquilla, Not set

Oncomedica S.A. ( Site 1098), Monteria, Not set

Instituto Cancerologico de Narino Ltda ( Site 1097), Pasto, Not set

Centre Jean Perrin ( Site 1181), Clermont Ferrand, Not set

Institut Paoli Calmettes ( Site 1182), Marseille, Not set

Groupe Hospitalier Broca Cochin Hotel Dieu ( Site 1183), Paris, Not set

Centre Eugene Marquis ( Site 1187), Rennes, Not set

Institut Curie - Centre Rene Huguenin ( Site 1185), Saint-Cloud, Not set

Universitaetsklinikum Carl Gustav Carus ( Site 1211), Dresden, Not set

Universitaetsklinikum Duesseldorf ( Site 1220), Duesseldorf, Not set

Universitatsklinikum Essen AoR ( Site 1213), Essen, Not set

Universitatsklinikum Hamburg-Eppendorf ( Site 1212), Hamburg, Not set

Gynoncological Practice Lueck. Schrader. Noeding ( Site 1224), Hannover, Not set

Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 1214), Kiel, Not set

Rotkreuzklinikum Muenchen gGmbH. Studienzentrale Frauenklinik ( Site 1225), Muenchen, Not set

Klinikum Oldenburg AoeR ( Site 1218), Oldenburg, Not set

Universitaet Regensburg ( Site 1221), Regensburg, Not set

Soroka Medical Center ( Site 1363), Beer-Sheva, Not set

Rambam Medical Center ( Site 1364), Haifa, Not set

Shaare Zedek Medical Center ( Site 1366), Jerusalem, Not set

Hadassah Medical Center. Ein Kerem ( Site 1367), Jerusalem, Not set

Rabin Medical Center ( Site 1365), Petah Tikva, Not set

Chaim Sheba Medical Center ( Site 1361), Ramat Gan, Not set

Sourasky Medical Center ( Site 1362), Tel Aviv, Not set

Centro di Riferimento Oncologico de Aviano Istituto Nazionale Tumori ( Site 1243), Aviano, Not set

A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1245), Bolgna, Not set

Istituto Nazionale Tumori ( Site 1251), Milano, Not set

Istituto Europeo di Oncologia ( Site 1250), Milano, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1242), Napoli, Not set

Policlinico Universitario -Agostino Gemelli ( Site 1241), Roma, Not set

The Jikei University Kashiwa Hospital ( Site 1701), Kashiwa, Chiba

National Cancer Center Hospital East ( Site 1704), Kashiwa, Chiba

Ehime University Hospital ( Site 1693), Toon, Ehime

Kurume University Hospital ( Site 1692), Kurume, Fukuoka

National Hospital Organization Hokkaido Cancer Center ( Site 1700), Sapporo, Hokkaido

Hyogo Cancer Center ( Site 1705), Akashi, Hyogo

Iwate Medical University Hospital ( Site 1695), Shiwa-gun, Iwate

University of the Ryukyus Hospital ( Site 1706), Nakagami-gun, Okinawa

Saitama Medical University International Medical Center ( Site 1691), Hidaka, Saitama

Shizuoka Cancer Center Hospital and Research Institute ( Site 1703), Sunto-gun, Shizuoka

National Cancer Center Hospital ( Site 1702), Tokyo, Not set

The Jikei University Hospital ( Site 1697), Tokyo, Not set

The Cancer Institute Hospital of JFCR ( Site 1698), Tokyo, Not set

Keio University Hospital ( Site 1699), Tokyo, Not set

Keimyung University Dongsan Medical Center ( Site 1603), Daegu, Not set

Seoul National University Hospital ( Site 1602), Seoul, Not set

Asan Medical Center ( Site 1601), Seoul, Not set

Samsung Medical Center ( Site 1604), Seoul, Not set

Medical Care and Research S.A. de C.V. ( Site 1135), Merida, Yucatan

Centro Estatal de Cancerologia de Chihuahua ( Site 1123), Chihuahua, Not set

Consultorio de Medicina Especializada del Sector Privado ( Site 1129), Ciudad de Mexico, Not set

CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 1127), Ciudad de Mexico, Not set

Instituto Nacional de Cancerologia. ( Site 1130), Mexico, Not set

Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 1125), San Pedro Garza Garcia, Not set

Faicic S de RL de CV ( Site 1133), Veracruz, Not set

Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 1152), Trujillo, La Libertad

Centro Medico Monte Carmelo ( Site 1156), Arequipa, Not set

Hospital Nacional Guillermo Almenara Irigoyen ( Site 1158), Lima, Not set

Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 1157), Lima, Not set

Instituto Nacional de Enfermedades Neoplasicas ( Site 1153), Lima, Not set

Hospital Nacional Arzobispo Loayza ( Site 1159), Lima, Not set

Hospital Nacional Maria Auxiliadora ( Site 1155), Lima, Not set

Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1331), Kazan, Not set

FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 1334), Moscow, Not set

Medical Rehabilitation Center ( Site 1337), Moscow, Not set

Novosibirsk Regional Clinical Oncology Dispensary ( Site 1358), Novosibirsk, Not set

Municipal Clinical Oncology Center ( Site 1346), Saint Petersburg, Not set

National Research Ogarev Mordovia State University ( Site 1347), Saransk, Not set

National Medical Research Center of Oncology n.a. N. N. Petrov ( Site 1348), St. Petersburg, Not set

Tomsk Scientific Research Institute of Oncology ( Site 1360), Tomsk, Not set

Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1345), Ufa, Not set

Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1275), Doniostia - San Sebastian, Guipuzcoa

Hospital Quiron Madrid ( Site 1277), Pozuelo de Alarcon, Madrid

Hospital Germans Trias i Pujol. ICO de Badalona ( Site 1276), Badalona, Not set

MD Anderson Cancer Center Madrid ( Site 1273), Madrid, Not set

Hospital Universitario Virgen Macarena ( Site 1274), Sevilla, Not set

Kaohsiung Veterans General Hospital ( Site 1632), Kaohsiung, Not set

China Medical University Hospital ( Site 1635), Taichung, Not set

Taichung Veterans General Hospital ( Site 1634), Taichung, Not set

Koo Foundation Sun Yat-Sen Cancer Center ( Site 1636), Taipei, Not set

Taipei Veterans General Hospital ( Site 1631), Taipei, Not set

Chang Gung Medical Foundation. Linkou ( Site 1633), Taoyuan, Not set

Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 1457), Adana, Not set

Hacettepe University Medical Faculty ( Site 1459), Ankara, Not set

Baskent Universitesi Ankara Hastanesi ( Site 1451), Ankara, Not set

Akdeniz Universitesi Tip Fakultesi ( Site 1453), Antalya, Not set

Medeniyet University Goztepe Egitim ve Arastırma Hast. Merdivenkoy ( Site 1458), Istanbul, Not set

Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 1456), Izmir, Not set

Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 1452), Konya, Not set

City Clinical Hosp.4 of DCC ( Site 1482), Dnipropetrovsk, Not set

MI Precarpathian Clinical Oncology Center ( Site 1487), Ivano-Frankivsk, Not set

Communal non profit enterprise Regional Clinical Oncology Center ( Site 1489), Kharkiv, Not set

National Cancer Institute of the MoH of Ukraine ( Site 1484), Kyiv, Not set

MI Odessa Regional Oncological Centre ( Site 1493), Odesa, Not set

Medical Centre LLC Oncolife ( Site 1485), Zaporizhzhya, Not set

Conditions: Cervical Cancer

Learn More ›

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864

Recruiting

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: Research Site, Daphne, Alabama +299 locations

Research Site, Daphne, Alabama

Research Site, Springdale, Arkansas

Research Site, Duarte, California

Research Site, Glendale, California

Research Site, Sacramento, California

Research Site, Santa Rosa, California

Research Site, Aurora, Colorado

Research Site, New Haven, Connecticut

Research Site, Jacksonville, Florida

Research Site, Miami, Florida

Research Site, Palm Bay, Florida

Research Site, Plantation, Florida

Research Site, Atlanta, Georgia

Research Site, Honolulu, Hawaii

Research Site, Chicago, Illinois

Research Site, Decatur, Illinois

Research Site, Elmhurst, Illinois

Research Site, Naperville, Illinois

Research Site, New Albany, Indiana

Research Site, Des Moines, Iowa

Research Site, Lexington, Kentucky

Research Site, Louisville, Kentucky

Research Site, Baton Rouge, Louisiana

Research Site, Baltimore, Maryland

Research Site, Columbia, Maryland

Research Site, Boston, Massachusetts

Research Site, Worcester, Massachusetts

Research Site, Detroit, Michigan

Research Site, Grand Rapids, Michigan

Research Site, Saint Paul, Minnesota

Research Site, Hattiesburg, Mississippi

Research Site, Saint Louis, Missouri

Research Site, Albuquerque, New Mexico

Research Site, Albany, New York

Research Site, New York, New York

Research Site, Stony Brook, New York

Research Site, Cincinnati, Ohio

Research Site, Cleveland, Ohio

Research Site, York, Pennsylvania

Research Site, Providence, Rhode Island

Research Site, Chattanooga, Tennessee

Research Site, Nashville, Tennessee

Research Site, Dallas, Texas

Research Site, El Paso, Texas

Research Site, Flower Mound, Texas

Research Site, Fort Worth, Texas

Research Site, Houston, Texas

Research Site, Kingwood, Texas

Research Site, McKinney, Texas

Research Site, Sugar Land, Texas

Research Site, Charlottesville, Virginia

Research Site, Fairfax, Virginia

Research Site, Midlothian, Virginia

Research Site, Norfolk, Virginia

Research Site, Roanoke, Virginia

Research Site, Tacoma, Washington

Research Site, Madison, Wisconsin

Research Site, Buenos Aires, Not set

Research Site, Caba, Not set

Research Site, Ciudad Autonoma Bs As, Not set

Research Site, Rosario, Not set

Research Site, San Nicolas de Los Arroyos, Not set

Research Site, Camperdown, Not set

Research Site, Darlinghurst, Not set

Research Site, Heidelberg, Not set

Research Site, Melbourne, Not set

Research Site, Nedlands, Not set

Research Site, Waratah, Not set

Research Site, Barretos, Not set

Research Site, Curitiba, Not set

Research Site, Florianópolis, Not set

Research Site, Goiânia, Not set

Research Site, Itajai, Not set

Research Site, Porto Alegre, Not set

Research Site, Recife, Not set

Research Site, Sao Paulo, Not set

Research Site, São Paulo, Not set

Research Site, Teresina, Not set

Research Site, Barrie, Ontario

Research Site, Hamilton, Ontario

Research Site, Toronto, Ontario

Research Site, Greenfield Park, Quebec

Research Site, Montreal, Quebec

Research Site, Montréal, Quebec

Research Site, Regina, Saskatchewan

Research Site, Saskatoon, Saskatchewan

Research Site, Quebec, Not set

Research Site, Beijing, Not set

Research Site, Bengbu, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Chengdu, Not set

Research Site, Chongqing, Not set

Research Site, Fuzhou, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Harbin, Not set

Research Site, Hefei, Not set

Research Site, Ji Nan, Not set

Research Site, Nanchang, Not set

Research Site, Nanjing, Not set

Research Site, Nanning, Not set

Research Site, Shandong, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Tianjin, Not set

Research Site, Wenzhou, Not set

Research Site, Wuhan, Not set

Research Site, Xi'an, Not set

Research Site, Xiamen, Not set

Research Site, Xintai, Not set

Research Site, Xuzhou, Not set

Research Site, Zhengzhou, Not set

Research Site, Lille, Not set

Research Site, Lyon, Not set

Research Site, Paris, Not set

Research Site, Saint Herblain Cedex, Not set

Research Site, Toulouse Cedex 9, Not set

Research Site, Vandoeuvre-lès-nancy, Not set

Research Site, Villejuif, Not set

Research Site, Düsseldorf, Not set

Research Site, Essen, Not set

Research Site, Georgsmarienhütte, Not set

Research Site, Hamburg, Not set

Research Site, Hannover, Not set

Research Site, Heidelberg, Not set

Research Site, Heilbronn, Not set

Research Site, Leipzig, Not set

Research Site, Hong Kong, Not set

Research Site, Calicut, Not set

Research Site, Chennai, Not set

Research Site, Kochi, Not set

Research Site, Kolkata, Not set

Research Site, Marg Jaipur, Not set

Research Site, Mohali, Not set

Research Site, Mysuru, Not set

Research Site, Nagpur, Not set

Research Site, Nashik, Not set

Research Site, New Delhi, Not set

Research Site, Pondicherry, Not set

Research Site, Surat, Not set

Research Site, Thiruvananthapuram, Not set

Research Site, Vadodara, Not set

Research Site, Vishakapatnam, Not set

Research Site, Bergamo, Not set

Research Site, Empoli, Not set

Research Site, Milano, Not set

Research Site, Milan, Not set

Research Site, Modena, Not set

Research Site, Napoli, Not set

Research Site, Padova, Not set

Research Site, Reggio Emilia, Not set

Research Site, Roma, Not set

Research Site, Rozzano, Not set

Research Site, Akashi-shi, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chiba-shi, Not set

Research Site, Chuo-ku, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Fukushima-shi, Not set

Research Site, Gifu-shi, Not set

Research Site, Hidaka-shi, Not set

Research Site, Hiroshima-shi, Not set

Research Site, Isehara-shi, Not set

Research Site, Kamogawa-shi, Not set

Research Site, Kashiwa, Not set

Research Site, Kitaadachi-gun, Not set

Research Site, Koto-ku, Not set

Research Site, Kumamoto-shi, Not set

Research Site, Kurume-shi, Not set

Research Site, Matsuyama-shi, Not set

Research Site, Nagoya-shi, Not set

Research Site, Niigata-shi, Not set

Research Site, Nishinomiya-shi, Not set

Research Site, Okayama-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Osakasayama-shi, Not set

Research Site, Ota-shi, Not set

Research Site, Sapporo-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Shinagawa-ku, Not set

Research Site, Shinjuku-ku, Not set

Research Site, Tsu-shi, Not set

Research Site, Tsukuba, Not set

Research Site, Yokohama-shi, Not set

Research Site, Busan, Not set

Research Site, Daegu, Not set

Research Site, Goyang-si, Not set

Research Site, Seongnam-si, Not set

Research Site, Seoul, Not set

Research Site, CD Mexico, Not set

Research Site, Guadalajara, Not set

Research Site, Mexico City, Not set

Research Site, Mexico, Not set

Research Site, México, Not set

Research Site, Tuxtla Gutierrez, Not set

Research Site, Bacolod, Not set

Research Site, Cebu City, Not set

Research Site, Manila, Not set

Research Site, Muntinlupa City, Not set

Research Site, Quezon City, Not set

Research Site, San Juan, Not set

Research Site, Białystok, Not set

Research Site, Bydgoszcz, Not set

Research Site, Gdańsk, Not set

Research Site, Gdynia, Not set

Research Site, Konin, Not set

Research Site, Kraków, Not set

Research Site, Legnica, Not set

Research Site, Lublin, Not set

Research Site, Przemysl, Not set

Research Site, Warszawa, Not set

Research Site, Wroclaw, Not set

Research Site, Łódź, Not set

Research Site, Singapore, Not set

Research Site, Cape Town, Not set

Research Site, Johannesburg, Not set

Research Site, Paarl, Not set

Research Site, Pretoria, Not set

Research Site, Barcelona, Not set

Research Site, Granada, Not set

Research Site, Hospitalet deLlobregat, Not set

Research Site, Madrid, Not set

Research Site, Pamplona, Not set

Research Site, Santander, Not set

Research Site, Hsinchu, Not set

Research Site, Kaohsiung, Not set

Research Site, Taichung, Not set

Research Site, Tainan, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Bangkok, Not set

Research Site, Chiang Mai, Not set

Research Site, Dusit, Not set

Research Site, Khon Kaen, Not set

Research Site, Songkhla, Not set

Research Site, Ankara, Not set

Research Site, Besevler Ankara, Not set

Research Site, Izmir, Not set

Research Site, Küçükçekmece, Not set

Research Site, Samsun, Not set

Research Site, Cardiff, Not set

Research Site, Chelsea, Not set

Research Site, Leicester, Not set

Research Site, Liverpool, Not set

Research Site, London, Not set

Research Site, Oxford, Not set

Research Site, Surrey, Not set

Research Site, Sutton, Not set

Research Site, Taunton, Not set

Research Site, Hanoi, Not set

Research Site, Ho Chi Minh City, Not set

Research Site, Vinh, Not set

Conditions: Breast Cancer

Learn More ›

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03776812

Completed

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: Site Reference ID/Investigator #004, Birmingham, Alabama +23 locations

Site Reference ID/Investigator #004, Birmingham, Alabama

Site Reference ID/Investigator #038, Scottsdale, Arizona

Site Reference ID/Investigator #032, Denver, Colorado

Site Reference ID/Investigator #001, Chicago, Illinois

Site Reference ID/Investigator #106, Boston, Massachusetts

Site Reference ID/Investigator #128, Boston, Massachusetts

Site Reference ID/Investigator #051, New York, New York

Site Reference ID/Investigator #169, New York, New York

Site Reference ID/Investigator #170, New York, New York

Site Reference ID/Investigator #127, Pittsburgh, Pennsylvania

Site Reference ID/Investigator #135, Charlottesville, Virginia

Site Reference ID/Investigator #121, Milwaukee, Wisconsin

Site Reference ID/Investigator #109, Brussel, Not set

Site Reference ID/Investigator #119, Edegem, Not set

Site Reference ID/Investigator #108, Leuven, Not set

Site Reference ID/Investigator #117, Toronto, Ontario

Site Reference ID/Investigator #096, Montréal, Quebec

Site Reference ID/Investigator #122, Milan, Not set

Site Reference ID/Investigator #112, Napoli, Not set

Site Reference ID/Investigator #124, Roma, Not set

Site Reference ID/Investigator #115, Barcelona, Not set

Site Reference ID/Investigator #114, Madrid, Not set

Site Reference ID/Investigator #116, Madrid, Not set

Site Reference ID/Investigator #113, Valencia, Not set

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma

Learn More ›

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

NCT03474107

Active Not Recruiting

The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy. This study compared progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemothera... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: UCI Chao Family Comprehensive Cancer Center, Orange, California +157 locations

UCI Chao Family Comprehensive Cancer Center, Orange, California

University of California, Sacramento, California

Innovative Clinical Research, Whittier, California

University of Colorado, Denver, Colorado

Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut

Sylvester Comprehensive Cancer Center, Miami, Florida

Florida Hospital, Orlando, Florida

Rush University Medical Center, Chicago, Illinois

Norton Cancer Institute, Louisville, Kentucky

Dana-Farber Cancer Institute, Boston, Massachusetts

Nebraska Cancer Specialists, Omaha, Nebraska

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Long Island Jewish Medical Center, Lake Success, New York

Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York

White Plains Hospital Center for Cancer Care - Oncology Site, White Plains, New York

Toledo Clinic Cancer Center, Toledo, Ohio

Providence Portland Med Center, Portland, Oregon

University of Pennsylvania, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Lifespan Rhode Island Hospital, Providence, Rhode Island

Saint Francis Hospital, Greenville, South Carolina

HOPE Cancer Center of East Texas, Tyler, Texas

Benaroya Research Institute at Virginia Mason, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

Site AR54001, Buenos Aires, Not set

Site AU61006, Adelaide, Not set

Site AU61001, Miranda, Not set

Site AU61004, St. Leonards, Not set

Site AU61002, Sydney, Not set

Site AT43005, Linz, Not set

Site AT43001, Salzburg, Not set

Site AT43004, Wien, Not set

Site BE32011, Aalst, Not set

Site BE32007, Brussels, Not set

Site BE32013, Brussels, Not set

Site BE32010, Charleroi, Not set

Site BE32001, Gent, Not set

Site BE32008, Gent, Not set

Site BE32005, Hasselt, Not set

Site BE32003, Leuven, Not set

Site BE32009, Liège, Not set

Site CA15015, Calgary, Not set

Site CA15012, Edmonton, Not set

Site CA15014, London, Not set

Site CA15002, Montreal, Not set

Site CA15007, Montreal, Not set

Site CA15011, Oshawa, Not set

Site CA15004, Quebec, Not set

Site CA15008, Saskatoon, Not set

Site CA15001, Sherbrooke, Not set

Site CA15005, Toronto, Not set

Site CA15013, Vancouver, Not set

Site DK45003, Aalborg, Not set

Site DK45004, Copenhagen, Not set

Site DK45001, Herlev, Not set

Site FR33021, Besancon, Not set

Site FR33009, Bordeaux, Not set

Site FR33018, Bordeaux, Not set

Site FR33001, Brest, Not set

Site FR33016, Caen, Not set

Site FR33015, Lyon, Not set

Site FR33014, Marseille, Not set

Site FR33003, Nice, Not set

Site FR33022, Paris, Not set

Site FR33005, Pierre-Bénite, Not set

Site FR33004, Saint-Mande, Not set

Site FR33002, Strasbourg, Not set

Site FR33019, Toulouse, Not set

Site FR33006, Villejuif, Not set

Site DE49011, Essen, Not set

Site DE49008, Heidelberg, Not set

Site DE49010, Münster, Not set

Site DE49003, Tübingen, Not set

Site DE49009, Würzburg, Not set

Site IT39008, Arezzo, Not set

Site IT39019, Cremona, Not set

Site IT39010, Milan, Not set

Site IT39025, Modena, Not set

Site IT39013, Pisa, Not set

Site IT39014, Reggio Emilia, Not set

Site IT39004, Terni, Not set

Site JP81010, Hirosaki, Aomori

Site JP81014, Kashiwa, Chiba

Site JP81007, Sapporo, Hokkaido

Site JP81026, Sapporo, Hokkaido

Site JP81020, Tsukuba, Ibaraki

Site JP81018, Morioka, Iwate

Site JP81009, Kita-gun, Kagawa

Site JP81002, Yokohama, Kanagawa

Site JP81005, Sendai, Miyagi

Site JP81016, Osakasayama, Osaka

Site JP81024, Takatsuki, Osaka

Site JP81008, Bunkyo-ku, Tokyo

Site JP81012, Koto-ku, Tokyo

Site JP81013, Shinjuku-ku, Tokyo

Site JP81011, Ube, Yamaguchi

Site JP81015, Chiba, Not set

Site JP81019, Fukuoka, Not set

Site JP81023, Fukuoka, Not set

Site JP81004, Hiroshima, Not set

Site JP81001, Kyoto, Not set

Site JP81017, Niigata, Not set

Site JP81003, Okayama, Not set

Site JP81022, Osaka, Not set

Site JP81021, Tokushima, Not set

Site JP81006, Toyama, Not set

Site KR82006, Daejeon, Not set

Site KR82007, Goyang-Si, Not set

Site KR82012, Hwasun-gun, Not set

Site KR82002, Incheon, Not set

Site KR82001, Seongnam-si, Not set

Site KR82003, Seoul, Not set

Site KR82004, Seoul, Not set

Site KR82008, Seoul, Not set

Site KR82009, Seoul, Not set

Site KR82010, Seoul, Not set

Site KR82005, Shin, Not set

Site NL31002, Amsterdam, Not set

Site NL31003, Amsterdam, Not set

Site NL31009, Nijmegen, Not set

Site NL31001, Tilburg, Not set

Site PT35105, Lisboa, Not set

Site PT35102, Lisbon, Not set

Site PT35106, Porto, Not set

Site RU70002, Ivanovo, Not set

Site RU70009, Obninsk, Not set

Site RU70005, Omsk, Not set

Site RU70015, Vologda, Not set

Site ES34010, Badajoz, Not set

Site ES34002, Badalona, Not set

Site ES34001, Barcelona, Not set

Site ES34012, Barcelona, Not set

Site ES34023, Barcelona, Not set

Site ES34014, Córdoba, Not set

Site ES34003, Madrid, Not set

Site ES34013, Madrid, Not set

Site ES34015, Madrid, Not set

Site ES34017, Madrid, Not set

Site ES34011, Manresa, Not set

Site ES34019, Pamplona, Not set

Site ES34005, Seville, Not set

Site ES34007, Valencia, Not set

Site ES34008, Valencia, Not set

Site CH41002, Bern, Not set

Site CH41001, Chur, Not set

Site TW88602, Kaohsiung, Not set

Site TW88605, Kaohsiung, Not set

Site TW88606, Taichung, Not set

Site TW88601, Tainan, Not set

Site TW88604, Taipei, Not set

Site TW88607, Taoyuan, Not set

Site GB44005, London, Not set

Site GB44006, London, Not set

Site GB44002, Sheffield, Not set

Site GB44011, Southampton, Not set

Site GB44013, Sutton, Not set

Site GB44004, Wirral, Not set

Conditions: Ureteral Cancer, Urothelial Cancer, Bladder Cancer

Learn More ›

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969

Active Not Recruiting

The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

04/23/2025

Locations: Research Site, La Jolla, California +33 locations

Research Site, La Jolla, California

Research Site, Los Angeles, California

Research Site, Orange, California

Research Site, Ventura, California

Research Site, Atlanta, Georgia

Research Site, Coeur d'Alene, Idaho

Research Site, Boston, Massachusetts

Research Site, Ann Arbor, Michigan

Research Site, Grand Rapids, Michigan

Research Site, Buffalo, New York

Research Site, New York, New York

Research Site, Portland, Oregon

Research Site, San Antonio, Texas

Research Site, Charlottesville, Virginia

Research Site, Seattle, Washington

Research Site, Madison, Wisconsin

Research Site, Barrie, Ontario

Research Site, Toronto, Ontario

Research Site, Seongnam-si, Not set

Research Site, Seongnam-Si, Not set

Research Site, Seoul, Not set

Research Site, Badalona, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Majadahonda, Not set

Research Site, Pamplona, Not set

Conditions: Locally Advanced or Metastatic Solid Tumours

Learn More ›

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

NCT06360354

Recruiting

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

04/23/2025

Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +70 locations

Comprehensive Blood and Cancer Center, Bakersfield, California

City of Hope National Medical Center, Duarte, California

University of California San Diego Moores Cancer Center, La Jolla, California

Translational Research in Oncology US Inc, Trio Central Pharmacy, Los Angeles, California

University of California Los Angeles, Santa Monica, California

Rocky Mountain Cancer Centers, Aurora, Colorado

Hartford Hospital, Hartford, Connecticut

Yale University, New Haven, Connecticut

Norwalk Hospital, Norwalk, Connecticut

University of Chicago, Chicago, Illinois

Indiana University, Indianapolis, Indiana

Norton Cancer Institute, Louisville, Kentucky

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Washington University, Saint Louis, Missouri

University of Nebraska, Omaha, Nebraska

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Memorial Sloan Kettering Cancer Center, New York, New York

Duke University, Durham, North Carolina

Cleveland Clinic Foundation, Cleveland, Ohio

United States Oncology Regulatory Affairs Corporate Office, Nashville, Tennessee

Oncology Consultants Cancer Center, Houston, Texas

US Oncology Research Investigational Products Center, Irving, Texas

University of Virginia Cancer Center, Charlottesville, Virginia

Virginia Cancer Specialists PC, Fairfax, Virginia

Northwest Medical Specialties, PLLC, Tacoma, Washington

Northwest Cancer Specialists - Vancouver, Vancouver, Washington

Chris OBrien Lifehouse, Camperdown, New South Wales

GenesisCare -North Shore Oncology, St Leonards, New South Wales

The Queen Elizabeth Hospital, Woodville South, South Australia

Austin Health, Austin Hospital, Heidelberg, Victoria

Peter MacCallum Cancer Centre, Melbourne, Victoria

Epworth Healthcare, St Albans, Victoria

Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Not set

Universitair Ziekenhuis Antwerpen, Edegem, Not set

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Not set

Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta

Princess Margaret Cancer Centre, Toronto, Ontario

CHU de Quebec Hopital de l Enfant Jesus, Quebec, Not set

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei

Herlev og Gentofte Hospital, Herlev, Not set

Institut Bergonie, Bordeaux, Not set

Centre Georges Francois Leclerc, Dijon, Not set

Institut Paoli Calmettes, Marseille, Not set

Gustave Roussy, Villejuif, Not set

Universitaetsklinikum Essen, Essen, Not set

Universitaetsklinikum Heidelberg, Heidelberg, Not set

Universitaetsklinikum Wuerzburg, Wuerzburg, Not set

Alexandra Hospital, Athens, Not set

Saint Luke Hospital, Thessaloniki, Not set

General Hospital Of Thessaloniki Papageorgiou, Thessaloniki, Not set

Queen Mary Hospital, The University of Hong Kong, Hong Kong, Not set

Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Not set

IRCCS Istituto Clinico Humanitas, Rozzano MI, Not set

Centro Ricerche Cliniche Di Verona Societa responsabilita limitata, Verona, Not set

Aichi Cancer Center, Nagoya-shi, Aichi

National Cancer Center Hospital East, Kashiwa-shi, Chiba

Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama-shi, Kanagawa

National Cancer Center Hospital, Chuo-ku, Tokyo

Radboud Universitair Medisch Centrum, Nijmegen, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Andalucía

Hospital Universitari Vall d Hebron, Barcelona, Cataluña

Hospital General Universitario Gregorio Maranon, Madrid, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Queen Elizabeth Hospital Birmingham, Birmingham, Not set

Sarah Cannon Research Institute UK, London, Not set

Conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Learn More ›

A Study of LY3200882 in Participants With Solid Tumors

NCT02937272

Active Not Recruiting

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/17/2025

Locations: University of Louisville, Louisville, Kentucky +17 locations

Conditions: Solid Tumor

Learn More ›

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408

Active Not Recruiting

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/14/2025

Locations: Site 318, Phoenix, Arizona +116 locations

Site 318, Phoenix, Arizona

Site 277, Tucson, Arizona

Site 350, Irvine, California

Site 364, La Jolla, California

Site 150, Palo Alto, California

Site 278, San Francisco, California

Site 014, San Francisco, California

Site 316, Solvang, California

Site 032, Aurora, Colorado

Site 335, Miami Beach, Florida

Site 042, Weston, Florida

Site 009, Atlanta, Georgia

Site 272, Atlanta, Georgia

Site 372, Gainesville, Georgia

Site 291, Savannah, Georgia

Site 315, Evanston, Illinois

Site 314, Hinsdale, Illinois

Site 346, Urbana, Illinois

Site 339, Indianapolis, Indiana

Site 200, Overland Park, Kansas

Site 334, Overland Park, Kansas

Site 279, Louisville, Kentucky

Site 128, Boston, Massachusetts

Site 288, New Brunswick, New Jersey

Site 292, Albuquerque, New Mexico

Site 275, Flushing, New York

Site 298, Cincinnati, Ohio

Site 304, Cincinnati, Ohio

Site 280, Portland, Oregon

Site 317, Portland, Oregon

Site 049, Portland, Oregon

Site 337, Bethlehem, Pennsylvania

Site 127, Pittsburgh, Pennsylvania

Site 276, Rapid City, South Dakota

Site 368, Germantown, Tennessee

Site 281, Nashville, Tennessee

Site 229, Austin, Texas

Site 312, Bedford, Texas

Site 297, Fort Worth, Texas

Site 392, San Antonio, Texas

Site 301, The Woodlands, Texas

Site 300, Norfolk, Virginia

Site 365, Richmond, Virginia

Site 121, Milwaukee, Wisconsin

Site 393, Caba, Buenos Aires

Site 381, Ciudad Autonoma de Buenos Aire, Buenos Aires

Site 415, Ciudad de Cordoba, Cordoba

Site 401, Ciudad de Cordoba, Cordoba

Site 395, Ciudad de Cordoba, Cordoba

Site 404, Ciudad de Mendoza, Mendoza

Site 391, Rosario, Santa Fe

Site 412, Rosario, Santa Fe

Site 426, St. Leonards, New South Wales

Site 417, Benowa, Queensland

Site 414, Melbourne, Victoria

Site 419, Melbourne, Victoria

Site 328, Aalst, Not set

Site 109, Brussels, Not set

Site 326, Charleroi, Not set

Site 325, Hasselt, Not set

Site 108, Leuven, Not set

Site 327, Liège, Not set

Site 384, Salvador, Bahia

Site 424, Brasília, Brasília - DF

Site 382, Fortaleza, Ceara

Site 383, Belo Horizonte, Minas Gerais

Site 390, Natal, Rio Grande Do Norte

Site 413, São Paulo, SP

Site 421, Porto Alegre, Not set

Site 380, Rio De Janeiro, Not set

Site 376, São Paulo, Not set

Site 389, São Paulo, Not set

Site 413, São Paulo, Not set

Site 374, São Paulo, Not set

Site 001, São Paulo, Not set

Site 117, Toronto, Ontario

Site 273, Montréal, Quebec

Site 306, Lille, Not set

Site 347, Montpellier, Not set

Site 307, Nancy, Not set

Site 310, Nice, Not set

Site 289, Paris, Not set

Site 323, Plérin, Not set

Site 322, Budapest, Not set

Site 290, Debrecen, Not set

Site 348, Győr, Not set

Site 309, Haifa, Not set

Site 080, Jerusalem, Not set

Site 203, Tel Aviv, Not set

Site 321, Catania, Not set

Site 320, Legnago, Not set

Site 122, Milano, Not set

Site 295, Pavia, Not set

Site 161, Roma, Not set

Site 124, Rome, Not set

Site 293, Torino, Not set

Site 319, Treviso, Not set

Site 397, Gyeonggi-do, Not set

Site 399, Seoul, Not set

Site 398, Seoul, Not set

Site 403, Seoul, Not set

Site 400, Seoul, Not set

Site 396, Seoul, Not set

Site 402, Seoul, Not set

Site 409, Seoul, Not set

Site 341, Gdynia, Not set

Site 331, Poznań, Not set

Site 329, Siedlce, Not set

Site 349, Badalona, Not set

Site 311, San Sebastián, Not set

Site 330, Valencia, Not set

Site 367, Brighton, East Sussex

Site 351, Taunton, Somerset

Site 366, Cheltenham, Not set

Site 055, London, Not set

Site 344, Manchester, Not set

Site 345, Northwood, Not set

Conditions: Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Learn More ›

Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

NCT06783140

Not Yet Recruiting

This study will compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/11/2025

Locations: Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation

Learn More ›

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883

Recruiting

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

03/26/2025

Locations: Arizona Oncology Associates Professional Corporation, Tucson, Arizona +89 locations

Arizona Oncology Associates Professional Corporation, Tucson, Arizona

City of Hope National Medical Center, Duarte, California

University of California San Diego Moores Cancer Center, La Jolla, California

Loma Linda University Cancer Center, Loma Linda, California

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California

University of California Davis Medical Center, Sacramento, California

University of California San Francisco Mission Bay Campus, San Francisco, California

University of California Los Angeles, Santa Monica, California

Rocky Mountain Cancer Centers Denver Midtown, Denver, Colorado

Sarah Cannon Research Institute, Denver, Colorado

Yale New Haven Hospital, New Haven, Connecticut

Norwalk Hospital, Norwalk, Connecticut

Memorial Cancer Institute, Pembroke Pines, Florida

Moffitt Cancer Center, Tampa, Florida

Emory University, Atlanta, Georgia

Northwestern University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Indiana University, Indianapolis, Indiana

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Johns Hopkins University, Baltimore, Maryland

University of Michigan, Ann Arbor, Michigan

Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan

Washington University, Saint Louis, Missouri

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Columbia University Irving Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University, Durham, North Carolina

University of Cincinnati Medical Center, Cincinnati, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Providence Portland Medical Center, Portland, Oregon

Oregon Health and Science University, Portland, Oregon

Thomas Jefferson University, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

University of Pennsylvania, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Gibbs Cancer Center and Research Institute - Spartanburg, Spartanburg, South Carolina

Avera Cancer Institute, Sioux Falls, South Dakota

United States Oncology Regulatory Affairs Corporate Office, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Texas Oncology Central-South, Austin, Texas

Mary Crowley Cancer Research, Dallas, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

Oncology Consultants, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

US Oncology Research Investigational Products Center, The Woodlands, Texas

Texas Oncology Northeast Texas, Tyler, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

University of Virginia Cancer Center, Charlottesville, Virginia

Virginia Cancer Specialists, PC, Fairfax, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Northwest Medical Specialties, PLLC, Tacoma, Washington

Northwest Cancer Specialists - Vancouver, Vancouver, Washington

Nepean Cancer Centre, Kingswood, New South Wales

GenesisCare -North Shore Oncology, St Leonards, New South Wales

Icon Cancer Care South Brisbane, South Brisbane, Queensland

The Queen Elizabeth Hospital, Woodville South, South Australia

St John of God Healthcare, Subiaco, Western Australia

Medizinische Universitaet Graz, Graz, Not set

Landeskrankenhaus Salzburg, Salzburg, Not set

Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Not set

Universitair Ziekenhuis Antwerpen, Edegem, Not set

CHU de Quebec Hopital de l Enfant Jesus, Quebec, Not set

Charite Universitaetsmedizin Berlin, Campus Virchow, Berlin, Not set

Universitaetsklinikum Dresden, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

Universitatsklinikum Koln, Koeln, Not set

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

Centro Ricerche Cliniche Di Verona Societa responsabilita limitata, Verona, Not set

Aichi Cancer Center, Nagoya-shi, Aichi

National Cancer Center Hospital East, Kashiwa-shi, Chiba

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo

Seoul National University Hospital, Seoul, Not set

The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Universitair Medisch Centrum Utrecht, Utrecht, Not set

Hospital Universitari Vall d Hebron, Barcelona, Cataluña

Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña

Institut Catala d Oncologia Hospitalet Hospital Duran i Reynals, Hospitalet de Llobregat, Cataluña

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid

Hospital Universitario Ramon y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Not set

Sarah Cannon Research Institute UK, London, Not set

Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Learn More ›

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

NCT02879318

Completed

The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: Tom Baker Cancer Centre, Calgary, Alberta +26 locations

Tom Baker Cancer Centre, Calgary, Alberta

BCCA - Vancouver Cancer Centre, Vancouver, British Columbia

CancerCare Manitoba, Winnipeg, Manitoba

The Moncton Hospital, Moncton, New Brunswick

The Vitalite Health Network - Dr. Leon Richard, Moncton, New Brunswick

Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador

QEII Health Sciences Centre, Halifax, Nova Scotia

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario

Kingston Health Sciences Centre, Kingston, Ontario

Grand River Regional Cancer Centre, Kitchener, Ontario

London Regional Cancer Program, London, Ontario

Ottawa Hospital Research Institute, Ottawa, Ontario

Algoma District Cancer Program, Sault Ste. Marie, Ontario

Niagara Health System, St. Catharines, Ontario

Odette Cancer Centre, Toronto, Ontario

University Health Network, Toronto, Ontario

St. Joseph's Health Centre, Toronto, Ontario

Hopital de la Cite-de-la-Sante, Laval, Quebec

L'Hotel-Dieu de Levis, Levis, Quebec

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec

The Jewish General Hospital, Montreal, Quebec

The Research Institute of the McGill University, Montreal, Quebec

Centre Integre Universitaire De Sante Et De Services, Montreal, Quebec

CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City, Quebec

Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec

Allan Blair Cancer Centre, Regina, Saskatchewan

Saskatoon Cancer Centre, Saskatoon, Saskatchewan

Conditions: Pancreatic Adenocarcinoma

Learn More ›